US FDA Approves New Imbruvica/Ibrutinib Formulation

On February 16, 2018, Imbruvica (ibrutinib) was approved by the US FDA in multiple strengths as a 140, 280, 420, and 460 mg tablet.

The new formulations are now commercially available, and the original 140 mg capsule will no longer be available after May 15, 2018. Please see the full Prescribing Information (link is external) for indications, dosage and usage.

Learn more about this new development about Imbruvica.